The Clarity study will assess the clinical and economic value of Aclarion’s Nociscan in spine surgery. The medtech company reached full funding for the trial with nearly $20 million, according to a Feb. 4 news release.
Nicholas Theodore, MD, of Baltimore-based Johns Hopkins, is leading the trial. Patients who are scheduled to have surgery for 1- or 2- level discogenic low back pain will be included, and they’ll all have a Nociscan before their procedures.
